SPONSORED CONTENT
The 340B Drug Pricing Program is at a crossroads, facing increased scrutiny, manufacturer restrictions, and ongoing legal battles. In this must-watch webinar, industry experts Ted Slafsky (340B Report), Emily Cook (McDermott, Will & Emery), and Nicole Shoquist (JPS Health Network) break down the biggest challenges ahead and what covered entities need to prepare for in 2025 and beyond.
A glimpse of what you’ll learn:
Key topics include: legislative and legal developments, the impact of contract pharmacy restrictions, and the push for greater transparency in how 340B savings are used. Whether you’re navigating compliance, advocating for the program, or strategizing for the future, this discussion offers critical insights and actionable takeaways.
